about
Genome-wide association studies identify four ER negative-specific breast cancer risk lociGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancerMusculoskeletal adverse events associated with adjuvant aromatase inhibitors.Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycosideGermline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Tumor homologous recombination deficiency assays: another step closer to clinical application?19p13.1 is a triple-negative-specific breast cancer susceptibility locus.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Identification of four novel susceptibility loci for oestrogen receptor negative breast cancerBiology and Management of Patients With Triple-Negative Breast Cancer.Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.Targeting the androgen receptor in triple-negative breast cancer: current perspectives.Association analysis identifies 65 new breast cancer risk loci.Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.Collision tumour of the breast composed of Merkel cell carcinoma and invasive ductal carcinoma: a case report.PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index scoreFailure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimensImpact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer
P50
Q24622610-73E664C9-85A1-4067-A8A2-1739308D9A8EQ29417100-D568E283-CBAC-4C9B-9F93-52C3718BDC8DQ30252854-38B6E5C6-7409-42C9-8227-E4A18B138EEBQ31043651-6BC400C1-B799-4DC2-BDF8-D97EB7DFD559Q34102670-D05299C5-6F12-4573-98C0-3874604272CAQ34143532-27B9ECF7-98B6-498F-A3E2-F16F14FD72B4Q34203765-6FD0CD2D-1C68-4CB0-829D-DF3109BF31FEQ34228853-1F0C0AF4-6028-400F-8203-C89A881536FFQ34279148-2D33826B-664F-4098-B865-356A74CC8202Q34996647-9592D249-4321-40C3-8813-C080048D7C8EQ35664732-7FCD964F-4D6C-451A-823A-F3E1DD220B1EQ35871567-405CFCDC-67DB-4847-8501-941E9F7D9F97Q35957703-FF39234B-F30B-4BC8-B5CE-269158353C88Q36356727-D5197080-3F98-45EE-A288-D93901AE3620Q36859142-06A1E486-81C5-4C67-ABB0-77D59080DD8BQ38893074-54DB07A0-637A-4B74-B343-6BD676A95FA9Q39309547-5C4D026F-B359-4FE6-A48B-F352C066EBBAQ39683758-A3881ED7-EBBC-48D9-9C6B-3D5B052BBEF8Q42364449-6C30BB65-1304-48D2-8A24-4A6B8905FB10Q45979098-391A535F-D066-46D7-BDE2-13D1FB379B39Q46103372-284A9CE5-80C2-4E69-87A5-9B6191DDD35CQ48168393-4CA77FB5-38F4-4A60-974E-CC1C31A9ADD2Q51136160-709EA972-B246-4C06-8356-CCA8411DDCEFQ53471085-56152E8D-6522-4449-8FE8-82EDE547A4C7Q64998946-D6448706-52A4-4EF3-BE54-107C236937D1Q79768609-943EB08D-80FB-4E20-90CA-60FEA7AA5308Q80586579-5D0A3913-EE9F-4B6F-8A61-D15BC8106932Q85650689-4091C1F4-E761-45AE-86DC-AE3988502530
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Priyanka Sharma
@ast
Priyanka Sharma
@en
Priyanka Sharma
@es
Priyanka Sharma
@nl
type
label
Priyanka Sharma
@ast
Priyanka Sharma
@en
Priyanka Sharma
@es
Priyanka Sharma
@nl
altLabel
Sharma P
@en
prefLabel
Priyanka Sharma
@ast
Priyanka Sharma
@en
Priyanka Sharma
@es
Priyanka Sharma
@nl
P106
P31
P496
0000-0001-8592-2239